Total trials
78
Active
21
Phase 3
2
Total enrollment
8,296
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Floradapt Intensive GI | — | — | — | — | — | 1 | |
| growth factors to help in regeneration | — | — | — | — | — | 1 | |
| N-Acetyl Cysteine | — | — | — | — | — | 1 |
Next readouts
- 2026-02-24
- 2026-04
- 2027-06-30
Top conditions
- Depression4
- Low Back Pain3
- Amyotrophic Lateral Sclerosis (ALS)3
- HIV Infection2
- Substance Abuse2
- HIV Infections2
- Heart Failure2
- Visual Function2
Frequently asked questions about Nova Southeastern University
- How many clinical trials does Nova Southeastern University have on ClinicalTrials.gov?
- Nova Southeastern University is listed as the lead sponsor on 78 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Nova Southeastern University's trials are in Phase 3?
- 2 of Nova Southeastern University's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Nova Southeastern University focus on?
- Nova Southeastern University's most-studied conditions on ClinicalTrials.gov are Depression, Low Back Pain, Amyotrophic Lateral Sclerosis (ALS), HIV Infection, Substance Abuse.
- When are Nova Southeastern University's next clinical trial readouts?
- Nova Southeastern University has 3 upcoming primary-completion readouts tracked here; the soonest is “The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome”, expected around 2026-02-24.